Next-generation allergy vaccines refer to allergen-derived attenuated molecules that can boost allergen-blocking IgG response. These IgG antibodies are specifically directed toward the IgE epitope of allergens and interfere in allergen-IgE interaction. Our study is a computational approach to design such vaccines against four widespread pan-allergens families. Pan-allergens display extensive immunological cross-reactivity due to the presence of conserved IgE epitope and T cell epitope. In this study, the vaccine design is based on hapten–carrier concept in which the carrier protein is an immunogenic component providing T cell help. Either PreS protein of hepatitis B or cholera enterotoxin B (CTB) fused with three tetanus toxoid fragments (TTFrC) was used here as the carrier. The hapten components are nonanaphylactic peptides (NAPs) derived from experimentally determined antigenic regions of the allergens. The charged residues of NAPs are selectively modified to obliterate IgE, as well as T cell reaction, and hence, are safe to apply in allergy patients. Various combinations of vaccine constructs (PreS/CTB+TTFrC and NAPs) were designed with intermediate linker motifs. Screening of constructs was performed through a three-step method such as physicochemical parameters, secondary structures, and tertiary structures using various bioinformatic tools. The final construct with best quality and stability was selected for each allergen family. Suitability of these constructs for being expressed in recombinant form was checked at DNA, RNA, and protein level. Presence of putative epitopes inducing tolerogenic interleukin-10 was also predicted for these constructs. The present work led to the design of putative vaccines with immunotherapeutic potential and broad applicability for allergic diseases caused by a wide array of cross-reactive allergens.
Get full access to this article
View all access options for this article.
References
1.
GenuneitJ, SeiboldAM, ApfelbacherCJ, KonstantinouGN, KoplinJJ, La GruttaS, LoganK, PerkinMR, and FlohrC: Task Force ‘Overview of Systematic Reviews in Allergy Epidemiology (OSRAE)’of the EAACI Interest Group on Epidemiology. Overview of systematic reviews in allergy epidemiology. Allergy, 2017; 72:849–856.
2.
vonMutiusE: Influences in allergy: Epidemiology and the environment. J Allergy Clin Immunol, 2004; 113:373–379.
3.
SichererSH, and SampsonHA: Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment. J Allergy Clin Immunol, 2014; 133:291–307.
4.
BaldacciS, OmenaasE, and OryszczynMP: Allergy markers in respiratory epidemiology. Eur Respir J, 2001; 17:773–790.
5.
PomésA, DaviesJM, GadermaierG, HilgerC, HolzhauserT, LidholmJ, LopataAL, MuellerGA, NandyA, RadauerC, and ChanSK: WHO/IUIS allergen nomenclature: Providing a common language. Mol Immunol, 2018; 100:3–13.
6.
BufeA, SpangfortMD, KahlertH, SchlaakM, and BeckerWM: The major birch pollen allergen, Bet v 1, shows ribonuclease activity. Planta, 1996; 199:413–415.
7.
AalberseRC, AkkerdaasJ, and Van ReeR: Cross-reactivity of IgE antibodies to allergens. Allergy, 2001; 56:478–490.
8.
HauserM, RouliasA, FerreiraF, and EggerM: Panallergens and their impact on the allergic patient. Allergy Asthma Clin Immunol, 2010; 6:1–4.
9.
ValentaR, SeiberlerS, NatterS, MahlerV, MossabebR, RingJ, and StinglG: Autoallergy: A pathogenetic factor in atopic dermatitis?. J Allergy Clin Immunol, 2000; 105:423–427.
10.
HolgateST, and PolosaR: Treatment strategies for allergy and asthma. Nat Rev Immunol, 2008; 8:218–230.
11.
MaloneM, and KennedyTM: Review: Side effects of some commonly used allergy medications (decongestants, anti-leukotriene agents, antihistamines, steroids, and zinc) and their safety in pregnancy. Int J Aller Medications, 2017;3. https://clinmedjournals.org/articles/ijam/international-journal-of-allergy-medications-ijam-3-024.php (Accessed April1, 2022).
12.
Focke-TejklM, and ValentaR: Safety of engineered allergen-specific immunotherapy vaccines. Curr Opin Allergy Clin Immunol, 2012; 12:555.
13.
ValentaR, CampanaR, Focke-TejklM, and NiederbergerV: Vaccine development for allergen-specific immunotherapy based on recombinant allergens and synthetic allergen peptides: Lessons from the past and novel mechanisms of action for the future. J Allergy Clin Immunol, 2016; 137:351–357.
14.
DorofeevaY, ShilovskiyI, TulaevaI, Focke-TejklM, FlickerS, KudlayD, KhaitovM, KarsonovaA, RiabovaK, KaraulovA, and KhanferyanR: Past, present, and future of allergen immunotherapy vaccines. Allergy, 2021; 76:131–149.
15.
ChapmanMD, PomésA, BreitenederH, and FerreiraF: Nomenclature and structural biology of allergens. J Allergy Clin Immunol, 2007; 119:414–420.
16.
SircarG, SarkarD, BhattacharyaSG, and SahaS: Allergen databases. In: Immunoinformatics. Humana Press, New York, NY, 2014, pp. 165–181.
17.
SircarG, SahaB, BhattacharyaSG, and SahaS: In silico prediction of allergenic proteins. In: Immunoinformatics. Humana Press, New York, NY, 2014, pp. 375–388.
18.
NairS, KukrejaN, SinghBP, and AroraN: Identification of B cell epitopes of alcohol dehydrogenase allergen of Curvularialunata. PLoS One, 2011; 6:e20020.
19.
PrickettSR, RollandJM, and O'HehirRE: Immunoregulatory T cell epitope peptides: The new frontier in allergy therapy. Clin Exp Allergy, 2015; 45:1015–1026.
20.
SircarG, JanaK, DasguptaA, SahaS, and BhattacharyaSG: Epitope mapping of Rhi o 1 and generation of a hypoallergenic variant: A candidate molecule for fungal allergy vaccines. J Biol Chem, 2016; 291:18016–18029.
21.
XuLL, GassetM, LinH, YuC, ZhaoJL, DangXW, and LiZX: Identification of the dominant T-cell epitopes of Lit v 1 shrimp major allergen and their functional overlap with known B-cell epitopes. J Agric Food Chem, 2021; 69:7420–7428.
22.
TophofMA, HermannsA, AdeltT, EberleP, GronkeC, FriedrichsF, KnechtR, MönterE, SchöpferH, SchwerkN, and SteinbachJ: Side effects during subcutaneous immunotherapy in children with allergic diseases. Pediatr Allergy Immunol, 2018; 29:267–274.
23.
LinhartB, and ValentaR: Mechanisms underlying allergy vaccination with recombinant hypoallergenic allergen derivatives. Vaccine, 2012; 30:4328–4335.
24.
WoodfolkJA, and Platts-MillsTA: Diversity of the human allergen-specific T cell repertoire associated with distinct skin test reactions: Delayed-type hypersensitivity-associated major epitopes induce Th1-and Th2-dominated responses. J Immunol, 2001; 167:5412–5419.
25.
FockeM, LinhartB, HartlA, WiedermannU, SperrWR, ValentP, ThalhamerJ, KraftD, and ValentaR: Non-anaphylactic surface-exposed peptides of the major birch pollen allergen, Bet v 1, for preventive vaccination. Clin Exp Allergy, 2004; 34:1525–1533.
26.
NiespodzianaK, Focke-TejklM, LinhartB, CivajV, BlattK, ValentP, van HageM, GrönlundH, and ValentaR: A hypoallergenic cat vaccine based on Fel d 1–derived peptides fused to hepatitis B PreS. J Allergy Clin Immunol, 2011; 127:1562–1570.
27.
Focke-TejklM, WeberM, NiespodzianaK, NeubauerA, HuberH, HenningR, StegfellnerG, MadereggerB, HauerM, StolzF, and NiederbergerV: Development and characterization of a recombinant, hypoallergenic, peptide-based vaccine for grass pollen allergy. J Allergy Clin Immunol, 2015; 135:1207–1217.
28.
BanerjeeS, WeberM, BlattK, SwobodaI, Focke-TejklM, ValentP, ValentaR, and VrtalaS: Conversion of Der p 23, a new major house dust mite allergen, into a hypoallergenic vaccine. J Immunol, 2014; 192:4867–4875.
29.
RadauerC, BublinM, WagnerS, MariA, and BreitenederH: Allergens are distributed into few protein families and possess a restricted number of biochemical functions. J Allergy Clin Immunol, 2008; 121:847–852.
30.
KadamK, KarbhalR, JayaramanVK, SawantS, and Kulkarni-KaleU: AllerBase: A comprehensive allergen knowledgebase. Database 2017;2017. https://academic.oup.com/database/article/doi/10.1093/database/bax066/4157991?login=false (Accessed April1, 2022).
YoshidaK, KurodaD, KiyoshiM, NakakidoM, NagatoishiS, SogaS, ShiraiH, and TsumotoK: Exploring designability of electrostatic complementarity at an antigen-antibody interface directed by mutagenesis, biophysical analysis, and molecular dynamics simulations. Sci Rep, 2019; 9:1.
33.
KolaskarAS, and TongaonkarPC: A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett, 1990; 276:172–174.
34.
GargVK, AvashthiH, TiwariA, JainPA, RamketePW, KayasthaAM, and SinghVK: MFPPI–multi FASTA ProtParam interface. Bioinformation, 2016; 12:74.
35.
McGuffinLJ, BrysonK, and JonesDT: The PSIPRED protein structure prediction server. Bioinformatics, 2000; 16:404–405.
36.
YangJ, YanR, RoyA, XuD, PoissonJ, and ZhangY: The I-TASSER Suite: Protein structure and function prediction. Nat Methods, 2015; 12:7–8.
37.
GuexN, and PeitschMC: SWISS-MODEL and the Swiss-Pdb Viewer: An environment for comparative protein modeling. Electrophoresis, 1997; 18:2714–2723.
38.
GreenerJG, KandathilSM, and JonesDT: Deep learning extends de novo protein modeling coverage of genomes using iteratively predicted structural constraints. Nat Commun, 2019; 10:1–3.
39.
AndersonRJ, WengZ, CampbellRK, and JiangX: Main-chain conformational tendencies of amino acids. Proteins: Struct Funct Bioinform, 2005; 60:679–689.
40.
LindingR, JensenLJ, DiellaF, BorkP, GibsonTJ, and RussellRB: Protein disorder prediction: Implications for structural proteomics. Structure, 2003; 11:1453–1459.
41.
GroteA, HillerK, ScheerM, MünchR, NörtemannB, HempelDC, and JahnD: JCat: A novel tool to adapt codon usage of a target gene to its potential expression host. Nucleic Acids Res, 2005; 33:W526–W531.
42.
ZukerM: Mfold web server for nucleic acid folding and hybridization prediction. Nucleic Acids Res, 2003; 31:3406–3415.
43.
NagpalG, UsmaniSS, DhandaSK, KaurH, SinghS, SharmaM, and RaghavaGP: Computer-aided designing of immunosuppressive peptides based on IL-10 inducing potential. Sci Rep, 2017; 7:1–10.
44.
Ertekin Ö, AkçaelE, KocaağaH, and ÖztürkS: Biological activity of the carrier as a factor in immunogen design for haptens. Molecules, 2018; 23:2977.
45.
KlinglmayrE, HauserM, ZimmermannF, DissertoriO, LacknerP, WopfnerN, FerreiraF, and WallnerM: Identification of B-cell epitopes of Bet v 1 involved in cross-reactivity with food allergens. Allergy, 2009; 64:647–651.
46.
LeungPS, ChowWK, DuffeyS, KwanHS, GershwinME, and ChuKH: IgE reactivity against a cross-reactive allergen in crustacea and mollusca: Evidence for tropomyosin as the common allergen. J Allergy Clin Immunol, 1996; 98:954–961.
47.
vanReeR, VoitenkoV, van LeeuwenA, and AalberseRC: Profilin is a cross-reactive allergen in pollen and vegetable foods. Int Arch Allergy Immunol, 1992; 98:97–104.
48.
GhoshN, SircarG, AsamC, WolfM, HauserM, SahaS, FerreiraF, and BhattacharyaSG: Purification and biochemical characterization of Hel a 6, a cross-reactive pectate lyase allergen from Sunflower (Helianthus annuus L.) pollen. Sci Rep, 2020; 10:1–5.
49.
BiedermannT, WintherL, TillSJ, PanznerP, KnulstA, and ValovirtaE: Birch pollen allergy in Europe. Allergy, 2019; 74:1237–1248.
50.
Kleine-TebbeJ, Ackermann-SimonJ, and HanfG: Molecular allergy diagnosis using pollen marker allergens and pollen panallergens: Five patterns seen in multiple test reactions to pollen extracts. Allergologie Select, 2021; 5:180.
51.
CiprandiG, ComiteP, MussapM, De AmiciM, QuagliniS, BarocciF, MarsegliaG, and ScalaE: Profiles of birch sensitization (Bet v 1, Bet v 2, and Bet v 4) and oral allergy syndrome across Italy. J Investig Allergol Clin Immunol, 2016; 26:244–248.
52.
WensingM, AkkerdaasJH, van LeeuwenWA, StapelSO, Bruijnzeel-KoomenCA, AalberseRC, BastBJ, KnulstAC, and van ReeR: IgE to Bet v 1 and profilin: Cross-reactivity patterns and clinical relevance. J Allergy Clin Immunol, 2002; 110:435–442.
53.
IbrahimEH, AsiriR, and Al SyaadK: Genetic fusion of tetanus toxin fragment C (Hc) gene to cholera toxin subunit B (CTB) gene as a preparatory step for double vaccine production. Gene Rep, 2018; 10:90–96.
54.
JacksonRJ, FujihashiK, Xu-AmanoJI, KiyonoH, ElsonCO, and McGheeJR: Optimizing oral vaccines: Induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant. Infect Immun, 1993; 61:4272–4279.
55.
TouraniM, KarkhahA, and NajafiA: Development of an epitope-based vaccine inhibiting immune cells rolling and migration against atherosclerosis using in silico approaches. Comput Biol Chem, 2017; 70:156–163.
56.
MarthK, BreyerI, Focke-TejklM, BlattK, ShamjiMH, LayhadiJ, GierasA, SwobodaI, ZafredD, KellerW, and ValentP: A nonallergenic birch pollen allergy vaccine consisting of hepatitis PreS–fused Bet v 1 peptides focuses blocking IgG toward IgE epitopes and shifts immune responses to a tolerogenic and Th1 phenotype. J Immunol, 2013; 190:3068–3078.
57.
TabeshS, FanuelS, FazlollahiMR, YekaninejadMS, KardarGA, and RazaviSA: Design and evaluation of a hypoallergenic peptide-based vaccine for Salsola kali allergy. Int Immunopharmacol, 2019; 66:62–68.
58.
NugrahaR, KamathSD, JohnstonE, KarnaneediS, RuethersT, and LopataAL: Conservation analysis of B-cell allergen epitopes to predict clinical cross-reactivity between shellfish and inhalant invertebrate allergens. Front Immunol, 2019; 10:2676.
59.
Van KampenV, LiebersV, SanderI, ChenZ, BaurX, Raulf-HeimsothM, and FalkenbergFW: B-cell epitopes of the allergen Chi t 1.01: Peptide mapping of epitopes recognized by rabbit, murine, and human antibodies. Allergy, 2001; 56:118–125.
60.
DatemaMR, EllerE, ZwindermanAH, PoulsenLK, VersteegSA, van ReeR, and Bindslev-JensenC: Ratios of specific IgG4 over IgE antibodies do not improve prediction of peanut allergy nor of its severity compared to specific IgE alone. Clin Exp Allergy, 2019; 49:216–226.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
